Alumis recently reported positive topline Phase 3 ONWARD1 and ONWARD2 results for its oral TYK2 inhibitor envudeucitinib in ...
5don MSN
HC Wainwright & Co. hikes Alumis Inc. (ALMS)’s price target to $40 from $20, reiterates buy rating
Alumis Inc. (NASDAQ:ALMS) is among the 14 best booming stocks to buy right now. On January 9, HC Wainwright & Co. lifted its ...
Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune ...
The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14 ...
Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...
The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.
Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...
Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.
Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback